Clinical trials: Empagliflozin
Hepatic Insufficiency, Healthy
Pharmacokinetics of Empagliflozin (BI 10773) in Patients With Impaired Liver Function
The main objective of this study is to assess the effect of mild, moderate and severe hepatic impairment on the pharmacokinetics, safety and tolerability of BI 10773 following oral administration of BI 10773 as a single dose.
- Trial name
- NCT01111318
- Testing
- BI 10773
- Where
- Romania
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
Pharmacodynamics and Pharmacokinetics of Empagliflozin and Torasemide in Patients With Type 2 Diabetes
The primary objective of the study is to investigate the effect of BI 10773, hydrochlorothiazide and torasemide on changes in serum and urine electrolytes.
- Trial name
- NCT01276288
- Testing
- BI 10773, hydrochlorothiazide, torasemide
- Where
- Germany
- Volunteers
- 23 people
- Sponsor
- Boehringer Ingelheim
Bioequivalence Study in Healthy Subjects
Clinical Study to Determine Bioequivalence Between Two Oral Medications of Empagliflozin/Metformin in 5 mg / 850 mg Tablets Under Fed Conditions.
Prospective, longitudinal, single-dose, randomized, open-label, crossover 2x2, two treatments, two periods, two sequences controlled clinical study
- Trial name
- ACL24-PC018 (NCT07633015)
- Testing
- Test. Empagliflozin/metformin 5/850 mg, Synjardy 5/850 mg tablet, Reference
- Where
- Mexico
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- ADIUM
Type 2 Diabetes, Dyslipidemias
To Evaluate the Safety and Pharmacokinetic Interaction Between HODO-22251 and HODO-22252 in Healthy Adults
The purpose of this study is to evaluate pharmacokinetic interaction and safety of co-administrated 25mg of Empagliflozin and 10/10mg Ezetimibe/Rosuvastatin in steady state in healthy volunteers.
- Trial name
- NCT06578676
- Testing
- Empagliflozin 25 MG, Ezetimibe/Rosuvastatin 10/10mg, Empagliflozin 25 MG with Ezetimibe/Rosuvastatin 10/10mg
- Where
- South Korea
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Hyundai Pharm
Diabetes Mellitus Type 2
SGLT2 Inhibition and Left Ventricular Mass
Patients with type 2 diabetes mellitus are exposed to an excessive heart failure risk secondary to left ventricular hypertrophy and impaired diastolic filling, a condition not addressed by currently available treatments.
- Trial name
- EMPATROPHY (NCT02728453)
- Testing
- Empagliflozin, Glimepiride
- Where
- Germany
- Volunteers
- 7 people
- Sponsor
- Hannover Medical School
Acute Heart Failure, Chronic Kidney Diseases
Empagliflozin in Acute Heart Failure
The objective is to study in a prospective, interventional, single arm, cohort study the potential synergistic diuretic effect of empagliflozin, in addition to furosemide, in hypervolemic patients admitted with acutely…
- Trial name
- DRIP-AHF-1 (NCT05305495)
- Testing
- Empagliflozin 25 MG
- Where
- Canada
- Volunteers
- 25 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Proteinuria, Diabetes (DM)
Proteinuria in Normotensive Diabetic Patients: ARBs Alone or in Combination of SGLT2i
Proteinuria is an early marker of diabetic kidney disease and predicts progression to chronic kidney disease and cardiovascular complications.
- Trial name
- NCT07586371
- Testing
- ARBs alone, ARBs in combination of SGLT2i
- Where
- Pakistan
- Volunteers
- 60 people
- Sponsor
- Dr Mudassar Saeed Pansota
Heart Failure, Diastolic, Diabetes Mellitus, Type 2
Effects of Empagliflozin on Exercise Capacity and Left Ventricular Diastolic Function in Patients With Heart Failure With Preserved Ejection Fraction and Type-2 Diabetes Mellitus
Patients enrolled into the study will be randomly allocated either to Empagliflozin group or control group. In the Empagliflozin group patients will be receiving standard care + Empagliflozin 10 mg o.d., in the control group…
- Trial name
- NCT03753087
- Testing
- Empagliflozin, Standard care
- Where
- Russia
- Volunteers
- 70 people
- Sponsor
- National Medical Research Center for Cardiology, Ministry of Health of Russian Federation
Polycystic Ovary Syndrome, Weight Gain
Empagliflozin vs Metformin on Metabolic Dysfunction in Polycystic Ovary Syndrome With or Without Comorbidity or Multimorbidity
this is open labelled randomize control trial among women with PCOS. PCOS, an endocrine condition, affects 5%-15% of premenopausal women.
- Conditions
- Polycystic Ovary Syndrome, Weight Gain, HbA1c
- Trial name
- NCT06140108
- Testing
- Empagliflozin 10 MG, MetFORMIN 500 Mg Oral Tablet
- Where
- Pakistan
- Volunteers
- 70 people
- Sponsor
- SINA Health Education and Welfare Trust
Polycystic Ovary Syndrome (PCOS)
Efficacy of Empagliflozin or Linagliptin as an Alternative to Metformin for Treatment of Polycystic Ovary Syndrome
The study aims to compare the efficacy of Empagliflozin or Linagliptin as an alternative to Metformin for treatment of non-diabetic patients with polycystic ovary syndrome (PCOS).
- Trial name
- NCT05200793
- Testing
- Empagliflozin 25 mg, Linagliptin 10 mg, Metformin 1500 mg
- Where
- Egypt
- Volunteers
- 75 people
- Sponsor
- Alexandria University
Type2diabetes
Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh
The study titled "Efficacy and Safety of Omarigliptin, A Weekly Dipeptidyl Peptidase-4 Inhibitor for Type 2 Diabetes Management: Real-World Evaluation in Bangladesh" aims to assess the real-world effectiveness and safety of…
- Trial name
- NCT06449235
- Testing
- Omarigliptin, Sulphonylureas, Metformin
- Where
- Bangladesh
- Volunteers
- 938 people
- Sponsor
- Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders
Type 1 Diabetes
SGLT2 Inhibitor Adjunctive Therapy to Closed Loop Control in Type 1 Diabetes Mellitus
The primary purpose of this study is to evaluate the safety and efficacy of combining SGLT2 inhibitors with closed loop control (CLC).
- Trial name
- CiQ-SGLT2 (NCT04201496)
- Testing
- Empagliflozin + Control-IQ x 4 wks then Basal-IQ x 2 wks, Empagliflozin + Basal-IQ x 2 wks then Control-IQ x 4 wks, No Empagliflozin + Control-IQ x 4 wks then Basal-IQ x 2 wks
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Ananda Basu, MD
Diabetic Retinopathy, Chronic Kidney Diseases
Effect of SGLT2 Inhibition on OCT-A Parameters in Diabetic CKD
Diabetes mellitus is a major and growing problem worldwide with many known micro and macrovascular complications. According to International Diabetes Federation, there were 285 million adults diagnosed with diabetes in 2010 and…
- Conditions
- Diabetic Retinopathy, Chronic Kidney Diseases, Diabetes Mellitus
- Trial name
- NCT04215445
- Testing
- Empagliflozin 25 MG, OCT-A
- Where
- Malaysia
- Volunteers
- 90 people
- Sponsor
- National University of Malaysia
Postprandial Hypoglycemia
Empagliflozin and Anakinra for the Treatment of Postprandial Hypoglycemia in Patients With Prediabetes
This study is to analyze whether the SGLT2-inhibitor empagliflozin or the IL-1 receptor antagonist anakinra may improve postprandial hypoglycemia in subjects with prediabetes.
- Trial name
- Hypo-PrEA (NCT05174507)
- Testing
- empagliflozin, anakinra
- Sponsor
- University Hospital, Basel, Switzerland
Type II Diabetes Mellitus, Efficacy, Self
Real World Safety & Efficacy Experience of Empagliflozin With or Without Metformin in T2DM Patients - EASE Study
Study Objective To evaluate the safety and tolerability of Empagliflozin with or without metformin in patients with Type II Diabetes Mellitus in the Pakistani population.
- Conditions
- Type II Diabetes Mellitus, Efficacy, Self, Safety Issues
- Trial name
- EASE (NCT05164263)
- Testing
- Empagliflozin
- Where
- 6 sites in Afghanistan, Kenya and 3 more
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Getz Pharma
Heart Failure, Cardiac Surgery
Discontinuation or Continuation of SGLT-2 Inhibitors Before Cardiac Surgery
SGLT-2 inhibitors are recommended treatments for managing heart failure patients. In cases of surgery, it is recommended to stop the treatment 3 days before surgery due to the risk of postoperative euglycemic diabetic…
- Trial name
- DISCO (NCT07766109)
- Testing
- treatment discontinuation, treatment continuation, ketone levels
- Where
- France
- Volunteers
- 434 people
- Sponsor
- University Hospital, Toulouse
Empaglifozin, Physiological Effects of Drugs
Sodium-glucose Co Transporter 2 (sGLT2) Inhibitor and Endogenous Ketone Production
Background: The drug empagliflozin treats diabetes. It lowers blood sugar by increasing glucose the kidneys excrete. This increases levels of ketones formed in the blood.
- Conditions
- Empaglifozin, Physiological Effects of Drugs, Hypoglycemic Agents, Sodium-Glucose Transporter 2 Inhibitors
- Trial name
- NCT03852901
- Testing
- empagliflozin (Jardiance) 25 mg
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- National Institute on Aging (NIA)
Diabetes Mellitus, Type 2
A Study to Test How Well Empagliflozin Works in Chinese Patients With Type 2 Diabetes Who Already Take Insulin
This is a study in Chinese adults with type 2 diabetes. The study is open to people who take insulin but still have too high blood sugar levels. Participants may additionally be taking up to 2 other medicines for their diabetes.
- Trial name
- NCT04233801
- Testing
- Empagliflozin
- Where
- 24 sites in China
- Volunteers
- 219 people
- Sponsor
- Boehringer Ingelheim
Effects of the DPP-4 Inhibitors or SGLT2 Inhibitors on the Protective Actions for Diabetic Complications
Metabolic and Cardiovascular Effects of Dipeptidyl Peptidase-4 (DPP-4) or Sodium-glucose Co-transporter Type 2 (SGLT2) Inhibitors
Inhibition of dipeptidyl peptidase-4 (DPP-4) or sodium-glucose co-transporter type 2 (SGLT2) has been proposed as a therapeutic target for type 2 diabetes.
- Trial name
- NCT02528019
- Testing
- DPP-4 inhibiotors, SGLT2 inhibitors, Glimepiride
- Where
- Japan
- Volunteers
- 100 people
- Sponsor
- Kurume University
Glomerulonephritis, Proteinuria
Empagliflozin in Patients With Glomerulonephritis
Sodium-glucose cotransporter 2 (SGLT2) inhibitors are newly developed antihyperglycemic medications. In addition to their glucose lowering properties, they have been shown to have favourable effects on the cardiovascular and…
- Trial name
- NCT05283057
- Testing
- Empagliflozin 25 MG
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- Kasr El Aini Hospital